BrainStorm Cell up after FDA considers Citizen Petition for ALS therapy review

Shares of drug developer BrainStorm Cell Therapeutics BCLI.O up 6.1% at $1.21 premarket

Co says FDA has considered a citizen petition requesting a new review of the data supporting co's therapy NurOwn for amyotrophic lateral sclerosis

A citizen petition to the FDA is a regulatory process, in which anyone can request the agency to act on specific issues like reviewing data, issuing new guidance, or enforcing actions

Co says the review "will provide a critical opportunity to reaffirm its potential as therapy for amyotrophic lateral sclerosis"

ALS is a rare and fatal neurodegenerative disease, which affects voluntary control of arms and legs, and leads to breathing trouble

BCLI says it supports exploration of potential regulatory pathways that may allow appropriate access to NurOwn for patients with ALS

Up to last close, stock down 49.8% YTD